asena

Anthony Sena

PhD Student

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Social:linkedin logotwitter logo github logo 

 

 

 

 

 

 

 

 

Background

Anthony Sena is currently Associate Director, Epidemiology Analytics within the Epidemiology department at Janssen Research & Development, a Johnson & Johnson company. His work and research are focused on using observational health data and real world evidence to advance global patient care and improve medical decision making. He is an active collaborator in the Observational Health Data Science and Informatics (OHDSI) initiative co-leading the ATLAS/WebAPI working group aimed at creating applications to carry out standardized epidemiology analytics. 

 

Publications

  1. Knowledge Base workgroup of the Observational Health Data Sciences and Informatics (OHDSI) collaborative. Large-scale adverse effects related to treatment evidence standardization (LAERTES): an open scalable system for linking pharmacovigilance evidence sources with clinical data. J Biomed Semantics. 2017 Mar 7;8(1):11. doi: 10.1186/s13326-017-0115-3. PubMed PMID: 28270198; PubMed Central PMCID: PMC5341176.
  2. Fife D, Cepeda MS, Baseman A, Richards H, Hu P, Starr HL, Sena AG. Medication changes after switching from CONCERTA(R) brand methylphenidate HCl to a generic long-acting formulation: A retrospective database study. PloS one. 2018;13(2):e0193453.
  3. Cepeda MS, Reps J, Sena AG, Ochs-Ross R. Risk Factors for Interstitial Cystitis in the General Population and in Individuals With Depression. International neurourology journal. 2019;23(1):40-5.
  4. Prieto-Alhambra D, Burn E, Weaver J, Sena AG, et al. OP0174 PARTIAL KNEE REPLACEMENT IS ASSOCIATED WITH A LOWER RISK OF VENOUS THROMBOEMBOLISM AND OPIOID USE THAN TOTAL KNEE REPLACEMENT BUT INCREASED RISK OF LONG-TERM REVISION: A MULTINATIONAL, MULTI-DATABASE, PROPENSITY SCORE-MATCHED, COHORT ANALYSIS INCLUDING OVER 280,000 PATIENTS. Annals of the Rheumatic Diseases 2019;78:163.
  5. Prieto-Alhambra, D., Bourke, A., Burkard, T., Burn, E., Costello, R., Culliford, D., Delmestri, A., Duarte-Salles, T., He, Y., John, L., Kolovos, S., Morales, D., O’Leary, C., Pinedo-Villanueva, R., Prats-Uribe, A., Reps, J., Robinson, D.E., Sena, A., Sproviero, W., Strauss, V., Williams, R.D., Yimer, B.B., Yu, D., & Ryan, P. (2019). DEVELOPMENT AND EXTERNAL VALIDATION OF A PATIENT-LEVEL PREDICTION MODEL FOR 60-DAY MORTALITY FOLLOWING TOTAL KNEE ARTHROPLASTY: A MULTINATIONAL COHORT STUDY. Osteoporosis International, 30.
  6. Wilcox, M.A., Villasis-Keever, A., Sena, A.G. et al. Evaluation of disability in patients exposed to fluoroquinolones. BMC Pharmacol Toxicol 21, 40 (2020). https://doi.org/10.1186/s40360-020-00415-4
  7. Burn, E., Weaver, J., Morales, D., Prats-Uribe, A., Delmestri, A., Strauss, V., Ying HE., Robinson, D., Pinedo-Villanueva, R., Kolovos, S., Duarte-Salles, T., Sproviero, W., Yu, D., Van Speybroeck, M., Williams, R., John, LH., Hughes, N., Sena AG., Costello, R., Birlie, B., Culliford, D., O’Leary, C., Morgan, H., Burkard, T., Prieto-Alhambra, D., Ryan, PB. (2019). Opioid use, postoperative complications, and implant survival after unicompartmental versus total knee replacement: a population-based network study. The Lancet Rheumatology 1(4): e229-e236.
  8. Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, Alser O, Alshammari TM, Biedermann P, Banda JM, Burn E, Casajust P, Conover MM, Culhane AC, Davydov A, DuVall SL, Dymshyts D, Fernandez-Bertolin S, Fišter K, Hardin J, Hester L, Hripcsak G, Kaas-Hansen BS, Kent S, Khosla S, Kolovos S, Lambert CG, van der Lei J, Lynch KE, Makadia R, Margulis AV, Matheny ME, Mehta P, Morales DR, Morgan-Stewart H, Mosseveld M, Newby D, Nyberg F, Ostropolets A, Park RW, Prats-Uribe A, Rao GA, Reich C, Reps J, Rijnbeek P, Sathappan SMK, Schuemie M, Seager S, Sena AG, Shoaibi A, Spotnitz M, Suchard MA, Torre CO, Vizcaya D, Wen H, de Wilde M, Xie J, You SC, Zhang L, Zhuk O, Ryan P, Prieto-Alhambra D; OHDSI-COVID-19 consortium. Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatol. 2020 Aug 21. doi: 10.1016/S2665-9913(20)30276-9. Epub ahead of print. PMID: 32864627; PMCID: PMC7442425.
  9. Burn, E., You, S.C., Sena, A.G. et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat Commun 11, 5009 (2020). https://doi.org/10.1038/s41467-020-18849-z

 

Posters

  1. Karcher H, Wiecek W, Nikodem M, Voss E.A, Sena A, Cepeda M.S. A new tool to automate Network Meta-Analyses (NMA) of studies extracted from ClinicalTrials.gov. ISPOR, Washington DC; May 2016
  2. Gold S, Blacketer M, Sena A, DeFalco FJ. CHRONOS: Cohort exploration through individual patient profiles. OHDSI Symposium, Washington, DC; September 2016
  3. Kern DM, Sena AG, Cepeda M.S. Using OHDSI tools to examine the comparability of chronic extended-release/long-acting (ER/LA) opioid users and chronic users of immediate-release/short-acting (IR/SA) opioids. OHDSI Symposium, Bethesda, MD; October 2018
  4. Burn E, Weaver J, Morales D, Prats-Uribe A, Delmestri A, Strauss V, Ying HE, Robinson D, Pinedo-Villanueva R, Kolovos S, Duarte-Salles T, Sproviero W, Yu D, Van Speybroeck M, Williams R, John LH, Hughes N, Sena AG, Costello R, Birlie B, Culliford D, O’Leary C, Morgan H, Burkhard T, Prieto-Alhambra D, Ryan PB. Emulating a randomized trial of unicompartmental and total knee replacement using real world evidence. OHDSI Europe Symposium, Rotterdam, Netherlands. March 2019
  5. Kern D, Cepeda MS, Sena A, Galpern W. PND62 TREATMENT PATTERNS IN PATIENTS NEWLY DIAGNOSED WITH PARKINSON’S DISEASE. Value in Health. 2019;22:S281. ISPOR, New Orleans, LA; May 2019
  6. Prieto-Alhambra D, Weaver J, Morgan-Stewart H, Sena A, Burn E, Ryan PB. Negative Control Outcomes to Control for Unmeasured Confounding in Device Safety Research: A Clinical Example. ICPE, Philadelphia, PA; August 2019
  7. Rijnbeek P, John L, Praet J, Sena A, Voss E, Blacketer C, Hughes N, et. al. The EHDEN Academy: Enabling Large-Scale Community Training. OHDSI Symposium, Bethesda, MD; September 2019
  8. Wilcox M, Villasis-Keever A, Sena A, Knoll C, Fife D. Evaluation of Disability in Patients Exposed to Fluroquinolones, J&J Excellence In Science Symposium, New Brunswick, NJ; November 2019
  9. Sena, AG., et al., THU0212 FIRST LINE TREATMENT WITH CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: A MULTINATIONAL POPULATION-BASED COHORT FROM 14 REAL WORLD HEALTHCARE DATABASES AND 9 COUNTRIES - REALITY VERSUS GUIDELINES, EULAR Congress; June 2020
  10. Sena, AG., et al., Secular trends in first line treatment with Disease Modifying Antirheumatic Drugs in Rheumatoid Arthritis: an international real-world study by the OHDSI and EHDEN networks. ICPE All Access; Spotlight Poster; September 2020

 

Presentations

  1. Sena AG, Boyce RD, Ryan PB, Schuemie MJ, Voss EA. Automated selection of Negative Control Exposure-Outcome pairs for use in Observational Studies: A capabilities demonstration. OHDSI Symposium, Washington DC; September 2016.
  2. Sena AG, Knoll C, Gifkins D, Ryan PB. Large Scale Risk Identification System for Proactive Safety Surveillance. OHDSI Symposium, Bethesda, MD; September 2017.
  3. Sena AG, Voss EA, Reps JM, Schuemie MJ. OHDSI Large Scale Analytics: A Modular Study Design Workflow. OHDSI Symposium, Bethesda, MD; October 2018
  4. Ryan PB, Feeney-Kostka K, Rao G, Sena AG, Klebanov G. An Overview of the OHDSI Analysis Ecosystem. OHDSI Symposium, Bethesda, MD; October 2018. https://www.ohdsi.org/past-events/2018-tutorials-overview-of-the-ohdsi-analysis-ecosystem/
  5. Sena AG, Reps JM, Schuemie MJ. OHDSI Standardized Analytics for Evidence Generation. OHDSI Europe Symposium, Rotterdam, Netherlands; March 2019.